When first-line treatments fail, should clozapine be considered for severe aggression in autistic youth? A retrospective chart review suggests reduced hospital visits and meaningful clinical improvement in carefully monitored patients. We review who might benefit—and how to balance efficacy with safety and monitoring demands.

Clozapine doesn’t fail. We fail to support it.